Long-term survival of a case with multiple liver metastases form duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy

World Journal of Gastroenterology

Volumn 12, Issue 17, 2006, Pages 2793-2797

  Sakakura, Chouhei ^a   Hagiwara, Akeo ^a   Soga, Koji ^a   Miyagawa, Koji ^a   Nakashima, Susumu ^a   Yoshikawa, Tetsuji ^a   Kin, Shuichi ^a   Nakase, Yuenn ^a   Yamaoka, Nobuki ^a   Sagara, Yoshihiko ^a   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

GIST; Imatinib mesylate; Liver metastases

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; CLINICAL PROTOCOL; DUODENUM CANCER; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD;

EID: 33744493151     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i17.2793     Document Type: Article

References (20)

1. Miettinen MM, Sarlomo-Rikala M, Kovatich AJ, Lasota J. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation. Mod Pathol 1999; 12: 756-762
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
3. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734
4. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990; 63: 195-201
5. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795
6. Plaaf BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, van der Graaf WT. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566
8. Druker BJ. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21: 239s-245s
9. Yasuoka R, Sakakura C, Shimomura K, Fujita Y, Nakanishi M, Aragane H, Hagiwara A, Bamba M, Abe T, Yamagishi H. Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor. Dig Surg 2003; 20: 183-191
10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
11. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349
12. Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crino L. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 2003; 16: 1041-1047
13. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 2003; 16: 1035-1040
14. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003; 2: 699-709
15. Singer G, Schraml P, Belgard C, Raggi A, Dirnhofer S, Went P, Mihatsch MJ, Moch H. KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst 2003; 95: 1009-1010
16. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138: 819-830
17. Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, Einhorn L. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-semi-nomatous germ-cell tumors. Ann Oncol 2003; 14: 873-880
18. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-279
19. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127: 294-299
20. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349